Zacks values NurExone at $2.55 per share—a huge upside from $0.54.
ExoPTEN, its breakthrough spinal cord treatment, shows promising results.
FDA Orphan Drug Designation gives it a strong competitive advantage.
If you missed the chance to invest in Bright Mind Biosciences and its remarkable 1,500%+ gain this week, don’t be frustrated. There’s another promising opportunity I’d like to introduce: NurExone (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90). Currently trading at just $0.54, with a market cap of $38M, this stock is a potential game-changer. While it’s easy to jump into any stock, NurExone stands out with multiple advantages. From its innovative technology to its strategic positioning, this company holds compelling reasons for you to consider taking a stake. Opportunities like this don’t come around often!
The Company
NurExone Biologic Inc. is pushing the boundaries of regenerative medicine with its innovative, non-invasive therapies targeting Central Nervous System (CNS) injuries. Their flagship product, ExoPTEN, has shown impressive results in preclinical studies for acute spinal cord injuries, successfully restoring motor function in 75% of treated rats. This is particularly noteworthy because ExoPTEN is delivered intranasally, making it a much less invasive option compared to traditional treatments.
One of the most exciting recent findings is that ExoPTEN can still effectively target the injury site up to one week after the injury occurs. This is a game changer because it extends the treatment window, giving more patients a chance to recover even if they don’t receive immediate care.
Dr. Lior Shaltiel, the CEO of NurExone, emphasizes how this could broaden the range of patients eligible for treatment, leading to better outcomes and making clinical trials easier to recruit for. With up to 500,000 new spinal cord injury cases reported globally each year, the ability to treat people even days after the injury has significant market potential and life-changing implications.
ExoPTEN could help recover motor function in 75% of spinal cord injury cases.
Effective up to 7 days post-injury, which could expand treatment options.
Potential to benefit up to 500,000 new spinal cord injury cases annually.
The Industry Issue
Current treatments for optic nerve damage, such as glaucoma, mainly aim to stop further harm but don’t repair the damage already done. NurExone Biologic is developing a new kind of treatment using exosome-loaded drugs like ExoPTEN, which could change this. Early studies show that ExoPTEN might actually help repair damaged nerves in the eye, offering new hope for conditions that were previously thought to be irreversible. This could be especially important for people with diseases like glaucoma, where nerve damage leads to vision loss.
The global market for optic nerve treatments was worth $3.4 billion in 2021 and is expected to grow to $5.3 billion by 2031. Major companies involved in developing these treatments include AbbVie, Novartis, Santen, and Teva Pharmaceuticals.
Current treatments focus on stopping further damage, but ExoPTEN may help repair nerves.
The market for optic nerve treatments is expected to grow significantly by 2031.
Leading companies in this space include AbbVie, Novartis, and others.
Recent Private Placement
NurExone Biologic recently announced a non-brokered private placement offering of up to 3,636,363 units at $0.55 per unit, with the aim of raising up to $2,000,000. Upon approval by the TSX Venture Exchange, the company will close on a first tranche of the offering, raising $1,610,147.55. The funds from this offering will be used to support the company’s working capital.
Dr. Lior Shaltiel, the CEO, expressed gratitude to their shareholders for their continued support, emphasizing how this investment reflects confidence in NurExone’s progress and vision. He highlighted the company’s efforts in advancing exosome-loaded therapies, which hold potential for treating multi-billion-dollar markets like spinal cord injuries and optic nerve damage.
Each unit in the offering includes one common share and one warrant. The warrant allows the holder to buy another share at $0.70 within 36 months. However, if the stock price exceeds $1.05 for 10 consecutive days, the company can accelerate the expiry of the warrants.
Private placement offering for $2 million, with an initial $1.61 million tranche.
Funds to be used for working capital to support growth.
Warrants have an accelerated expiry clause if stock price hits $1.05.
Zacks Small-Cap Research
Zacks Small-Cap Research initiated coverage on NurExone Biologic. Zacks values the stock at $2.55 per share, which is a major upside compared to its current price. With the FDA awarding it a valuable Orphan Drug Designation, NurExone is gaining credibility and protection from competition. Zacks is confident that once this treatment hits the market, it will be a game changer.
Conclusion
If you missed out on Bright Mind Biosciences’ explosive 1,500%+ gain, don’t worry—another major opportunity is here with NurExone (TSXV: NRX). Currently trading at just $0.54, NurExone is working on cutting-edge technology to treat spinal cord injuries, a field with massive potential. Zacks values the stock at $2.55 per share, signaling a substantial upside. With its innovative treatment ExoPTEN, FDA Orphan Drug Designation, and strategic market positioning, NurExone is well-placed for significant growth. This is your chance to invest early in a biotech company that could revolutionize regenerative medicine!
